-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Umpu4w2Dm7eFBE4akZBQXgopehKxwFoO9S6nUOHWMFjiYQhBOnBlgjV3mKNIiIhx
 Vx1hGMElpVpdcqM2vPCV+w==

<SEC-DOCUMENT>0001279569-09-000108.txt : 20090127
<SEC-HEADER>0001279569-09-000108.hdr.sgml : 20090127
<ACCEPTANCE-DATETIME>20090127143016
ACCESSION NUMBER:		0001279569-09-000108
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090127
FILED AS OF DATE:		20090127
DATE AS OF CHANGE:		20090127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-31062
		FILM NUMBER:		09547838

	BUSINESS ADDRESS:	
		STREET 1:		1167 KENSINGTON CRES NW SUITE 210
		STREET 2:		CALGARY ALBERTA CANADA T2N 1X7
		CITY:			ALBERTA CANADA
		STATE:			A0
		ZIP:			00000
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		210 - 1167 KENSINGTON CRES NW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2N 1X7
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>oncolytics6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html>
  <head>
    <title>oncolytics6k.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><!--
    PAGEBREAK -->

    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <hr style="MARGIN-TOP: -5px; COLOR: #000000" noshade size="4">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="1">
      <div style="FONT-SIZE: 14pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman">SECURITIES AND<font size="+0" style="FONT-SIZE: 14pt; FONT-FAMILY: Times New Roman"> EXCHANGE</font>
COMMISSION</font><br></font></font></font></font><font style="FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Washington, D.C.
20549</font></div>
      <div style="FONT-SIZE: 12pt" align="center">&#160;</div>
      <div style="FONT-SIZE: 18pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">F<font size="+0" style="FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman">orm</font>
6-K</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman">Report
of Foreign Private Issuer</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><font size="+0">Pursuant to Rule</font>&#160;13a-16 or 15d-16<br>of the Securities
Exchange Act of 1934</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">For the month of&#160;January 2009
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt" align="center">Commission File Number 000-31062
</div>
      <div>&#160;</div>
      <center>
        <div style="FONT-SIZE: 24pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">Onc<font size="+0" style="FONT-SIZE: 24pt; FONT-FAMILY: Times New Roman">oly</font>tics
Biotech Inc.</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Translation of registrant&#8217;s name
into English)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <center>
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Suite&#160;210, 1167 Kensington
Crescent NW<br>Calgary, Alberta, Canada T2N 1X7</font></div>
        <hr style="COLOR: black" align="center" noshade size="1" width="45%">
        <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-STYLE: italic">(Address of principal executive
offices)</font></div>
        <div style="FONT-SIZE: 10pt" align="center">&#160;</div>
      </center>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether the registrant files
or will file annual reports under cover Form&#160;20-F or Form&#160;40-F. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;20-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Form&#160;40-F&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(1):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(1) only permits the submission in paper of a Form&#160;6-K if
submitted solely to provide an attached annual report to security holders.
</div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark if the registrant is
submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T
Rule&#160;101(b)(7):&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Note: </font>Regulation&#160;S-T
Rule&#160;101(b)(7) only permits the submission in paper of a Form&#160;6-K if
submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant&#8217;s &#8220;home country&#8221;), or under the rules of the home country exchange on
which the registrant&#8217;s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant&#8217;s security holders, and, if discussing a material
event, has already been the subject of a Form&#160;6-K submission or other
Commission filing on EDGAR. </div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&#160;12g3-2(b) under the
Securities Exchange Act of 1934. </div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="70%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="49%">&#160;</td>
                <td width="2%">&#160;</td>
                <td width="49%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">
                  <div style="TEXT-ALIGN: center">Yes&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">o</font></div>
                </td>
                <td>&#160;</td>
                <td valign="top">
                  <div style="TEXT-ALIGN: center">No&#160;&#160;&#160;<font style="FONT-FAMILY: wingdings">&#254;</font></div>
                </td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt">&#160;</div>
      <div style="FONT-SIZE: 10pt">If &#8220;Yes&#8221; is marked, indicate below the file number
assigned to the registrant in connection with
Rule&#160;12g3-2(b):&#160;&#160;&#160;82&#160;-&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div>
      <div>&#160;</div>
      <div>
      </div>
      <div>&#160;</div>
      <hr style="MARGIN-TOP: -2px; COLOR: #000000" noshade size="1">
      <hr style="MARGIN-TOP: -10px; COLOR: #000000" noshade size="4">
      <div style="FONT-SIZE: 10pt">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div align="left">&#160;</div>
    <div>
    </div>
    <div>
    </div>
    <div>
      <div>
        <div align="left">
          <div align="left">
            <div align="left">
              <div align="left">
                <table cellpadding="0" cellspacing="0" width="100%">
                    <tr>
                      <td align="left" valign="bottom" width="6%" style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">EXHIBIT</font></div>
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">NUMBER</font></div>
                      </td>
                      <td valign="bottom" width="2%" style="PADDING-BOTTOM: 2px"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="68%" style="BORDER-BOTTOM: black 2px solid">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: left" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 8pt; FONT-FAMILY: times new roman">DESCRIPTION</font></div>
                      </td>
                    </tr>
                    <tr>
                      <td valign="top" width="6%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td valign="top" width="68%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                    </tr>
                    <tr>
                      <td align="left" valign="top" width="6%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">99.1</font></div>
                      </td>
                      <td valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">&#160;
      </font></td>
                      <td align="left" valign="top" width="68%">
                        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: times new roman, serif"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><font style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">News Release Dated
      January 27, 2009 -</font> <font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Oncolytics
      Biotech Inc. Announces Start of Patient Enrolment in </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Translational
      Clinical Trial Investigating REOLYSIN(R) in Patients with </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Metastatic
      Colorectal
Cancer</font></font></font></font></div>
                      </td>
                    </tr>
                </table>
              </div>
            </div>
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; TEXT-INDENT: 0pt"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
    </div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
      <div id="FTR">
        <div id="GLFTR" style="WIDTH: 100%" align="left">
        </div>
      </div>
      <div id="PN" style="PAGE-BREAK-AFTER: always">
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>&#160;</div>
    <div style="FONT-FAMILY: 'Times New Roman',Times,serif">
      <div style="FONT-SIZE: 10pt" align="center"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></div>
      <div>&#160;</div>
      <div style="FONT-SIZE: 10pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized. </div>
      <div>&#160;</div>
      <center>
        <div>
          <table border="0" cellpadding="0" cellspacing="0" width="100%" style="FONT-SIZE: 10pt">
              <tr valign="bottom">
                <td width="50%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="1%">&#160;</td>
                <td width="47%">&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" colspan="3" valign="top"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Oncolytics Biotech
      Inc.</font><br>(Registrant)</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
                <td>&#160;</td>
                <td align="left" valign="top">&#160;</td>
              </tr>
              <tr>
                <td>&#160;</td>
              </tr>
              <tr valign="bottom">
                <td valign="top">Date:&#160;&#160;January 27, 2009 </td>
                <td>&#160;</td>
                <td align="left" valign="top">By:</td>
                <td>&#160;</td>
                <td align="left" valign="top">/s/&#160;&#160;Doug Ball

                  <hr style="COLOR: black" align="left" noshade size="1" width="60%">      Doug Ball<br>Chief Financial Officer</td>
              </tr>
          </table>
        </div>
      </center>
      <div style="FONT-SIZE: 10pt" align="center">
      </div>
      <div>&#160;</div>
    </div><!-- PAGEBREAK -->

    <div>
    </div>
    <div>&#160;</div>
  </body>
</html>


</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991.htm
<DESCRIPTION>NEWS RELEASE DATED JANUARY 27, 2009
<TEXT>
<html>
  <head>
    <title>ex991.htm</title>
<!-- Licensed to: CNW Group-->
<!-- Document Created using EDGARizer 4.0.6.4 -->
<!-- Copyright 1995 - 2008 EDGARfilings, Ltd., an IEC company. All rights reserved -->
</head>
    <body bgcolor="#ffffff" style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
    <pre>Exhibit 99.1
</pre>
    <pre>News release via Canada NewsWire, Toronto 416-863-9350

           Attention Business/Medical Editors:
           Oncolytics Biotech Inc. Announces Start of Patient Enrolment in
           Translational Clinical Trial Investigating REOLYSIN(R) in Patients with
           Metastatic Colorectal Cancer

           CALGARY, Jan. 27 /CNW/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC,
NASDAQ:ONCY) announced today that patient enrolment has begun in a U.K.
translational clinical trial investigating intravenous administration of
REOLYSIN(R) in patients with metastatic colorectal cancer prior to surgical
resection of liver metastases. The principal investigator is Professor Alan
Melcher of St. James's University Hospital.
           "This study allows us to assess a resected tumour after REOLYSIN(R)
treatment has been administered, giving us vital information about how
effective REOLYSIN(R) delivery really is in patients," said Prof. Melcher.
"REOLYSIN(R) will be given to patients before their planned operation, which
is part of the patient's standard clinical care. In addition to possible
benefit to patients, this data will tell us more about how REOLYSIN(R) kills
cancer cells; helping to guide future research and development of the agent."
           The trial (REO 013) is an open-label, non-randomized, single centre study
of REOLYSIN(R) given intravenously to patients for five consecutive days in
advance of their scheduled operations to remove colorectal cancer deposits
metastatic to the liver. Patients will comprise two groups receiving
REOLYSIN(R), either at an early (21 to 10 days) or late time point (less than
10 days) before surgical resection. After surgery, the tumour and surrounding
liver tissue will be assessed for viral status and anti-tumour effects.
           "We are pleased that our U.K. colleagues are sponsoring additional
clinical research using REOLYSIN(R)," said Dr. Brad Thompson, President and
CEO of Oncolytics. "With the U.S. National Cancer Institute trials underway,
three REOLYSIN(R) trials are now being sponsored by our collaborators."
           The primary objectives of the trial are to assess the presence,
replication and anti-cancer effects of reovirus within liver metastases after
intravenous administration of REOLYSIN(R) by examination of the resected
tumour. Secondary objectives include assessing the anti-tumour activity and
safety profile of REOLYSIN(R), and monitoring the humoral and cellular immune
response to REOLYSIN(R).
           Eligible patients include those with histologically proven colorectal
cancer, planned for potentially curative surgical resection of liver
metastases. Up to 20 patients will receive one cycle of treatment in this
trial, with approximately 10 in each of the early and late virus groups.
           The University of Leeds is covering all costs of the trial, while
Oncolytics will provide REOLYSIN(R).

           About Oncolytics Biotech Inc.

           Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics'
clinical program includes a variety of Phase I and Phase II human trials using
REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com

           This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including the Company's expectations related to
the U.K. translational study for patients with metastatic colorectal cancer
with liver metastases, and the Company's belief as to the potential of
REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to differ
materially from those in the forward-looking statements. Such risks and
uncertainties include, among others, the availability of funds and resources
to pursue research and development projects, the efficacy of REOLYSIN(R) as a
cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test,
the success and timely completion of clinical studies and trials, the
Company's ability to successfully commercialize REOLYSIN(R), uncertainties
related to the research and development of pharmaceuticals and uncertainties
related to the regulatory process. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the forward
looking statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable laws.

           %SEDAR: 00013081E          %CIK: 0001130319

           /For further information: Oncolytics Biotech Inc.: Cathy Ward, 210, 1167
Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: (403) 670-7377, Fax: (403)
283-0858, cathy.ward(at)oncolytics.ca; The Equicom Group: Nick Hurst, 325, 300
5th Ave. SW, Calgary, Alberta, T2P 3C4, Tel: (403) 538-4845, Fax: (403)
237-6916, nhurst(at)equicomgroup.com; The Investor Relations Group: Erika Moran,
11 Stone St, 3rd Floor, New York, NY, 10004, Tel: (212) 825-3210, Fax: (212)
825-3229, emoran(at)investorrelationsgroup.com/
           (ONC. ONCY)

CO:  Oncolytics Biotech Inc.

CNW 11:34e 27-JAN-09

</pre>
  </body>
</html>


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
